Related Experiment Video
Updated: Apr 12, 2026
09:03
Murine Corneal Transplantation: A Model to Study the Most Common Form of Solid Organ Transplantation
Published on: November 17, 2014
10.3K
[Therapy for Ocular Graft-vs-Host Disease].
P Steven1, L Sauerbier1, S Siebelmann1
1Kompetenzzentrum Okuläre GvHD, Zentrum für Augenheilkunde, Uniklinik Köln.
Klinische Monatsblatter Fur Augenheilkunde
|May 20, 2015
Summary
Therapy for ocular graft-vs-host disease (ocular GvHD) presents challenges due to rapid progression. More research is needed to develop evidence-based treatments for preserving vision.
Area of Science:
- Ophthalmology
- Immunology
- Graft-vs-Host Disease
Context:
- Ocular graft-vs-host disease (GvHD) management is complex, with limited specific research.
- Current therapeutic recommendations often extrapolate from dry eye disease studies.
- Rapid and unpredictable disease progression complicates treatment strategies.
Purpose:
- To review current therapeutic strategies for ocular GvHD.
- To highlight the limitations in evidence-based treatment options.
- To identify primary therapeutic targets including anti-inflammation, anti-fibrosis, and ocular surface lubrication.
Summary:
- This review categorizes available ocular GvHD therapies into local, systemic, surgical, and prophylactic approaches.
- It emphasizes the lack of studies specifically investigating ocular GvHD treatments.
- The review underscores the need for dedicated research to guide clinical decision-making.
Impact:
- Highlights the urgent need for ocular GvHD-specific research to improve patient outcomes.
- Aims to inform ophthalmologists about current therapeutic options and their limitations.
- Provides a foundation for developing more effective, evidence-based treatment protocols for ocular GvHD.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:28Angle Closure Glaucoma: Treatment
1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
01:25Glaucoma: Overview
1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
01:23Ophthalmic Drug Delivery Systems
245
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
245